SMCC-DM1

SMCC-DM1 is a linker-payload intermediate used in the development and manufacture of antibody-drug conjugates (ADCs). It consists of the potent cytotoxic agent DM1 (mertansine), a derivative of the microtubule-disrupting maytansinoid family, covalently bonded to the heterobifunctional, non-cleavable crosslinker SMCC (succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate). In an ADC construct, the SMCC linker provides a stable attachment to lysine residues of the antibody. Upon internalization of the ADC into target cells and subsequent lysosomal degradation, the active metabolite lysine-SMCC-DM1 is released. This metabolite binds to tubulin, inhibiting microtubule polymerization and leading to cell cycle arrest in the G2/M phase and eventual apoptosis. This specific linker-payload combination is a key component of several oncology therapeutics, most notably the approved drug trastuzumab emtansine (Kadcyla). Chongqing Sintaho offers SMCC-DM1 as part of its specialized XDC toxin-linker portfolio for pharmaceutical research and development.

Other names

SMCC-mertansinesuccinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate-DM1